K. Abdallah's research while affiliated with Merck & Co. and other places
What is this page?
This page lists the scientific contributions of an author, who either does not have a ResearchGate profile, or has not yet added these contributions to their profile.
It was automatically created by ResearchGate to create a record of this author's body of work. We create such pages to advance our goal of creating and maintaining the most comprehensive scientific repository possible. In doing so, we process publicly available (personal) data relating to the author as a member of the scientific community.
If you're a ResearchGate member, you can follow this page to keep up with this author's work.
If you are this author, and you don't want us to display this page anymore, please let us know.
It was automatically created by ResearchGate to create a record of this author's body of work. We create such pages to advance our goal of creating and maintaining the most comprehensive scientific repository possible. In doing so, we process publicly available (personal) data relating to the author as a member of the scientific community.
If you're a ResearchGate member, you can follow this page to keep up with this author's work.
If you are this author, and you don't want us to display this page anymore, please let us know.
Publication (1)
Cancer immunotherapy has transformed the treatment of cancer. However, increasing use of immune-based therapies, including the widely used class of agents known as immune checkpoint inhibitors, has exposed a discrete group of immune-related adverse events (irAEs). Many of these are driven by the same immunologic mechanisms responsible for the drugs...
Citations
... 4 Without early identification and proper management, irAEs can develop into severe complications, resulting in treatment discontinuation or failure and even death, which poses a considerable challenge in daily clinical care. 5,6 Isolated RCTs and their meta-analyses present the highest quality of evidence and are the basis for guidelines issued by healthcare organisations. 7 However, the evaluation of entire profiles of rare irAEs derived from RCTs data is difficult owing to their stringent diagnostic standards and selection criteria, relatively small sample sizes, and limited follow-up duration. ...
![[object Object]](https://i1.rgstatic.net/ii/profile.image/272427129241603-1441963097101_Q64/Igor-Puzanov.jpg)
![[object Object]](https://i1.rgstatic.net/ii/profile.image/272365212925966-1441948335441_Q64/Clifton-Bingham.jpg)
